A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
Clinical trial NCT02318368 · TERMINATED
Trial details
- NCT number
- NCT02318368
- Sponsor
- AVEO Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-01
- Primary completion
- 2017-01-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.